Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 2 Central Nervous System Neoplasms 2 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Recurrence 1 Osteosarcoma 1 Oligodendroglioma 1 Hepatoblastoma 1 Glioma 1 Ganglioneuroblastoma 1 Astrocytoma 1

Interventions

Cyclophosphamide 8 dinutuximab 7 Magnetic Resonance Spectroscopy 7 Topotecan 6 Doxorubicin 6 sargramostim 5 Vincristine 5 Stem Cell Transplantation 5 Radiation 5 Platinum 5 Melphalan 5 Isotretinoin 5 Colony-Stimulating Factors 5 Cisplatin 5 Biopsy 5 1,2-diaminocyclohexaneplatinum II citrate 5 Temozolomide 4 Specimen Handling 4 Irinotecan 4 Etoposide 4 Congresses as Topic 4 Carboplatin 4 Thiotepa 3 Busulfan 3 3-Iodobenzylguanidine 3 etoposide phosphate 2 Razoxane 2 Dexrazoxane 2 temsirolimus 1 lorlatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ganglioneuroblastoma × Influenza Vaccines × CNS × Clear all

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡